HB Wealth Management LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 190.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,820 shares of the company’s stock after acquiring an additional 25,433 shares during the quarter. HB Wealth Management LLC’s holdings in Zoetis were worth $2,790,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the stock. RFG Advisory LLC boosted its position in shares of Zoetis by 4.9% in the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after purchasing an additional 80 shares during the period. Financial Engines Advisors L.L.C. increased its position in Zoetis by 4.4% during the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after buying an additional 87 shares during the period. Physician Wealth Advisors Inc. lifted its stake in Zoetis by 17.4% in the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock valued at $73,000 after buying an additional 91 shares during the last quarter. Smithfield Trust Co lifted its stake in Zoetis by 4.2% in the fourth quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock valued at $290,000 after buying an additional 92 shares during the last quarter. Finally, Howland Capital Management LLC boosted its holdings in shares of Zoetis by 4.5% in the second quarter. Howland Capital Management LLC now owns 2,137 shares of the company’s stock valued at $333,000 after acquiring an additional 92 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.
Wall Street Analysts Forecast Growth A number of equities analysts have recently issued reports on ZTS shares. Piper Sandler lowered their target price on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, August 10th. Barclays reduced their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Citigroup decreased their price target on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. William Blair reissued a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. Finally, UBS Group dropped their price objective on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $101.08.
Check Out Our Latest Stock Report on Zoetis Zoetis Stock Performance Shares of ZTS opened at $73.56 on Wednesday. The stock has a market capitalization of $30.40 billion, a P/E ratio of 12.12, a P/E/G ratio of 1.77 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. Zoetis Inc. has a 1 year low of $71.00 and a 1 year high of $152.12. The company’s fifty day moving average is $75.61 and its two-hundred day moving average is $92.87.
Zoetis (NYSE:ZTS – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s revenue was down .2% on a year-over-year basis. During the same quarter last year, the business earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.2 earnings per share for the current year.
About Zoetis (Free Report)
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Stories Five stocks we like better than Zoetis Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:50 p.m. ET.
Interested parties can access the live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.
Blackhill Capital Inc. cut its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 28.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 68,296 shares of the company’s stock after selling 27,603 shares during the quarter. Zoetis accounts for approximately 0.2% of Blackhill Capital Inc.’s holdings, making the stock its 20th biggest position. Blackhill Capital Inc.’s holdings in Zoetis were worth $4,908,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of ZTS. Prosperity Bancshares Inc acquired a new stake in Zoetis in the fourth quarter valued at about $25,000. Cassaday & Co Wealth Management LLC acquired a new position in Zoetis during the 1st quarter worth approximately $28,000. Elyxium Wealth LLC purchased a new position in shares of Zoetis during the 4th quarter worth approximately $32,000. Root Financial Partners LLC raised its stake in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares in the last quarter. Finally, Wellington Grp LLC lifted its holdings in shares of Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after buying an additional 267 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.
Zoetis Stock Performance NYSE:ZTS opened at $77.45 on Friday. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The company has a market capitalization of $32.00 billion, a P/E ratio of 12.76, a price-to-earnings-growth ratio of 1.75 and a beta of 0.74. The firm has a 50-day moving average price of $75.57 and a two-hundred day moving average price of $95.62. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $156.49.
Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year. Analyst Upgrades and Downgrades Several research firms have issued reports on ZTS. Citigroup cut their price objective on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. BNP Paribas Exane decreased their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. TD Cowen lowered their price target on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday. Barclays cut their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a report on Wednesday, July 1st. Finally, Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $107.43.
Check Out Our Latest Stock Analysis on Zoetis
About Zoetis (Free Report)
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Recommended Stories Five stocks we like better than Zoetis 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude? Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
Phibro Animal Health's Zoetis MFA acquisition has created a larger animal health platform with stronger earnings and broader manufacturing reach. Vaccines, nutritional specialties, and companion-animal expansion give PAHC newer growth verticals beyond the legacy MFA franchise. Management's optimization program and Chicago Heights consolidation could improve efficiency as the acquired portfolio moves beyond integration.
Dividend growth stocks can be attractive long-term buys, as the income they provide is likely to rise over time. But many stocks that have long streaks don't often raise their payouts at high rates, so while their streaks are getting longer, the increases don't often amount to much. Investors may be wondering what the point is at that stage, since it effectively becomes more about extending the streak rather than significantly growing dividend income.
The three dividend stocks on this list, however, have been generous with their dividend increases. They may not have exceptionally long track records of dividend growth, but over the past five years, they have more than doubled their payouts. The stocks I'm talking about are Tractor Supply Company (TSCO +2.68%), Zoetis (ZTS +2.64%), and Energy Transfer LP (ET +0.42%). They also have yields that are far higher than the S&P 500 average of just 1%.
Image source: Getty Images.
Tractor Supply CompanyTractor Supply Company sells essential products for farms, ranches, homes, and animals. The rural lifestyle retailer has thousands of stores throughout the country and has been around for over 85 years.
This year, however, the stock has struggled due to a poor outlook and weaker economic conditions, with discretionary spending down. The stock has fallen by more than 40% in just the past 12 months.
Today's Change
(
2.68
%) $
0.93
Current Price
$
35.65
As a long-term investment, however, there may be some intrigue here from investors. It trades at 18 times earnings and yields 2.8%. Its current quarterly dividend is 24 cents. It did a 5-for-1 stock split in 2024, so the 52-cent dividend it was paying in 2021 is the equivalent of 10.4 cents on a split-adjusted basis. Thus, its dividend has increased by around 131% since then.
Although the stock hasn't been doing that well of late, its payout ratio remains manageable at around 50%, suggesting there may still be room for more increases in the future. For investors willing to hang on and be patient, this may be a good, undervalued stock to buy right now.
ZoetisZoetis is an animal health company that makes a wide range of products for animals, including vaccines and medicines. Its business can generate a steady stream of income due to the necessities it offers.
However, like Tractor Supply, it's also been struggling of late due to economic challenges and questions about its future growth. Things haven't been great, but the company's sales are still up 1% over the first six months of the year, and its profits have declined by a modest 3%. The panic in the market may be a bit extreme.
Today's Change
(
2.64
%) $
1.95
Current Price
$
75.91
The sell-off in the stock has pushed its yield up to around 2.9%. Currently, it's paying investors 53 cents per share in dividends each quarter, up from 25 cents five years ago, which translates into an increase of 112%.
Its payout ratio is low at 34%, and at 12 times its trailing earnings, the stock's valuation is also low. For both contrarian and income-seeking investors, Zoetis is another stock that may prove to be an underrated buy in the long run.
Energy TransferUnlike the other stocks on this list, shares of Energy Transfer are up 24% over the past 12 months. The pipeline company has been benefiting from growing bullishness in the energy sector due to elevated oil prices. The company prides itself on "safely delivering America's energy" and being a key player in the sector.
During the first six months of the year, the company's revenue has grown by 54%, to $62.1 billion. Its business is benefiting from strong demand for natural gas liquids and increases in crude oil transportation.
Today's Change
(
0.42
%) $
0.09
Current Price
$
21.51
Even with its share price rising considerably over the past year, the stock still offers the highest yield on this list, paying around 6.4%. Its quarterly dividend is currently 34 cents, and that has increased by 123% from five years ago, when it was paying 15.25 cents per quarter.
The company's distributable cash flow in the most recent quarter rose by 32%, to $2.59 billion. That's a good sign that not only is the dividend in good shape, supported by strong financials, but that there may still be more room for it to rise higher.
For investors looking for a top energy stock to buy that also pays a high yield, Energy Transfer could make for an excellent option right now.
Zoetis is navigating the worst drawdown in its stock history, driven by weakening U.S. vet clinic traffic and heightened competition across key companion animal franchises. Despite aggressive competitor promotions, Zoetis protects industry-leading profitability (35%–37% EBIT margins) using targeted gross-to-net rebates rather than base list-price cuts. Trading at a historic low 12x P/E and a 7%+ FCF yield, Zoetis offers a strong margin of safety compared to its Base Case DCF fair value of $100.06.
Zoetis' Q2 earnings results were mixed, and the company cut its forward guidance. This has reduced the stock's margin of safety, but on balance, the risk/reward profile still favors the bulls. Zoetis has other segments performing well which partially offset the weakness in U.S. pet-related sales.
Zoetis (ZTS) now trades at just 12x forward earnings, with a nearly 3% dividend yield and gross margins above 70%, after a severe multiyear drawdown. Competition, weaker U.S. companion animal sales, and reduced guidance have pressured ZTS, but its core profitability and market dominance remain intact. Management is aggressively repurchasing shares, capital returns are strong, and the balance sheet remains healthy despite $9B in long-term debt.
The U.S. Food and Drug Administration on Thursday issued an emergency use authorization for Zoetis' flea and tick drug to treat New World screwworm (NWS) infestations in dogs and puppies.
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax, commonly called New World screwworm (NWS), feed on living tissues, such as open wounds, of animals including livestock, wildlife and pets, and can inflict damage, pain and even death if not treated.
As New World screwworm continues to threaten the U.S.1 -- recently prompting several states to issue formal orders requiring treatment of domestic animals as part of cross-border animal movement from infested areas -- Zoetis is closely monitoring the situation and is committed to helping veterinarians and dog owners be prepared with solutions. Under an EUA, the FDA authorizes the use of a medication in an emergency to treat or prevent life-threatening diseases or conditions when certain criteria are met.
“At Zoetis, our highest priority is protecting the health and well-being of animals,” said Abhay Nayak, EVP and President, U.S. Commercial Operations at Zoetis. “The Emergency Use Authorization for Simparica Trio provides an important new tool in the fight against New World screwworm, a devastating parasite that can cause severe suffering in dogs. With this milestone, Simparica Trio helps simplify parasite protection for dogs with a single monthly chew—supporting both routine control and New World screwworm response needs.”
“We are deeply committed to supporting our customers with trusted, science-driven solutions—especially when rapid response and preparedness on key public health issues are critical. This Emergency Use Authorization for Simparica Trio builds on Zoetis’ expanding, multi-species set of solutions to help address New World screwworm across both companion animals and livestock,” Nayak continued. “Zoetis remains dedicated to advancing animal health and delivering the confidence our customers rely on, backed by Zoetis’ science, quality and manufacturing scale – so more animals can be protected, more consistently.”
Simparica Trio was the first product FDA-approved to provide all-in-one protection for dogs against heartworm disease, ticks and fleas, roundworms, hookworms, and prevents flea tapeworm infections by killing fleas in a single monthly chewable. It is FDA-approved to kill six species of ticks, including the Gulf Coast tick – providing comprehensive tick protection. While found all over the nation, the Gulf Coast tick is native to Southern U.S. states, including Texas.
Pet owners are encouraged to work closely with their veterinarian if they have any concerns about New World screwworm or other parasites. Reports of any suspicious wounds, maggots, or infestations should be made to a local veterinarian, state animal health official or the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS). USDA APHIS animal health contacts can be found at https://www.aphis.usda.gov/contact/animal-health.
As the leading animal health company, Zoetis has long supported a One Health approach to emerging and transboundary infectious diseases and has a strong track record of quickly developing innovative solutions to provide veterinarians and animal owners with the right mix of tools to prevent, control and treat disease in animals.
IMPORTANT SAFETY INFORMATION for Simparica Trio
Use with caution in dogs with a history of seizures. Simparica Trio contains sarolaner, a member of the isoxazoline class which has been associated with neurologic adverse reactions including tremors, ataxia, and seizures in dogs with or without a history of neurologic disorders. The safe use of Simparica Trio has not been evaluated in breeding, pregnant, or lactating dogs. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea. See Full Prescribing Information at SimparicaTrioPI.com.
Treatment of New World screwworm in Other Species
In addition to the EUA for Simparica Trio, Zoetis offers Dectomax®-CA1 Injectable (doramectin injection), the only nonprescription conditionally approved parasite control product labeled for prevention and treatment of infestations caused by NWS larvae in cattle and for prevention of reinfestation for 21 days. This conditional approval applies to beef cattle, female dairy cattle less than 20 months of age, pregnant beef cows, newborn calves and bulls. Dectomax-CA1 is not for use in calves to be processed for veal. Dectomax-CA1 is not for use in female dairy cattle 20 months of age or older, except under the conditions of the Emergency Use Authorization (EUA) granted on May 19, 2026.
The U.S. Food and Drug Administration has issued an Emergency Use Authorization (EUA) for the use of the approved/conditionally approved products Dectomax/Dectomax-CA1 for the following indications:
The prevention and treatment of infestations caused by Cochliomyia hominivorax larvae (myiasis) in dairy cattle (lactating dairy cows, dry dairy cows, and replacement dairy heifers 20 months of age and older), except for calves to be processed for veal. The prevention of infestations caused by C. hominivorax larvae (myiasis) in swine, sheep except for lactating sheep, and deer. The prevention of infestations caused by C. hominivorax larvae (myiasis) in horses 1 year old and older. Early detection of New World screwworm and rapid response are crucial to protecting the health of companion animals and livestock.
Emergency Use Authorization for Simparica Trio for New World Screwworm
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Simparica Trio is not approved for this use.
Simparica Trio is approved for other uses in dogs and puppies.
For additional information on the EUA, please refer to the Simparica Trio EUA Fact Sheet.
Limitations of Authorized Use
Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner.
Approved Indications for Simparica Trio
Simparica Trio is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina) and hookworm (L4, immature adult, and adult Ancylostoma caninum and adult Uncinaria stenocephala) infections. Simparica Trio kills adult fleas (Ctenocephalides felis) and is indicated for the treatment and prevention of flea infestations, the prevention of Dipylidium caninum (tapeworm) infections as a direct result of killing Ctenocephalides felis vector fleas on the treated dog, and the treatment and control of tick infestations with Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (Asian longhorned tick) for one month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater. Simparica Trio is indicated for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.
Please refer to the following fact sheets for additional information:
EUA - Simparica Trio Fact Sheet
EUA - Dairy Cattle, Swine, Sheep and Deer Fact Sheet
EUA - Horse Fact Sheet
For more information on NWS, visit FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies
Dectomax-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under NADA 141-616.
Important Information:
Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
Dectomax-CA1 Injectable (Cattle only), as authorized under the Conditional Approval for use against New World screwworm, has a 35-day pre-slaughter withdrawal period. Do not use in calves to be processed for veal. Do not use in female dairy cattle 20 months of age or older, except under the conditions of the Emergency Use Authorization. Use in dogs may result in fatalities.
Dectomax/Dectomax-CA1 Injectable Emergency Use Authorization, authorized for the duration of the emergency declaration, does not provide full or conditional approval, but the Center for Veterinary Medicine (CVM) at the Food and Drug Administration (FDA) has determined that Dectomax/Dectomax-CA1 may be effective and safe. Dectomax/Dectomax-CA1 Injectable, as authorized under the Emergency Use Authorization for use against New World screwworm, has a 35-day pre-slaughter withdrawal period for lactating dairy cattle, dry dairy cattle, replacement dairy heifers, sheep and deer, and a 24-day pre-slaughter withdrawal period for swine. Treated calves and calves born to treated cows should not be processed for veal. Withhold milk from dairy cattle for 468 hours (19.5 days) after treatment has ended. Not for use in lactating sheep. Not for use in horses less than 1 year of age.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements which reflect the current views of Zoetis with respect to regarding products, product approvals or licenses, products under development and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
ZTS-COR
ZTS-IR
ZTS-CA
1 APHIS. Current Status of New World Screwworm | Screwworm.gov Accessed 6/3/26.
Index Dow Jones -0,06 % na 53757,51 b. S&P 500 +0,25 % na 7747,61 b. Nasdaq Composite +0,64 % na 26614,82 b.
Nejsledovanější americké indexy v úvodu středečního obchodování posilují. Agentura Bloomberg poznamenala, že jádrová inflace v USA byla v červenci utlumená, což pravděpodobně zmírní tlak na americký Fed, aby zvyšoval úrokové sazby. Index spotřebitelských cen po očištění o často volatilní ceny potravin a energií vzrostl meziměsíčně o 0,2 %. V meziročním vyjádření se zvýšil o 2,5 %, což odpovídá nejpomalejšímu tempu od března 2021. Celkové spotřebitelské ceny vzrostly oproti předchozímu měsíci o 0,1 % a meziročně o 3,4 %.
Inflační data tak podle Bloombergu přinášejí částečnou úlevu obchodníkům na Wall Street, kteří se obávají přetrvávajících geopolitických rizik, zatímco index S&P 500 se drží poblíž historických maxim. Náladě pomáhá také růst technologických společností spojených s rozmachem umělé inteligence. V popředí dnešního růstu jsou akcie společností poskytujících AI cloudovou infrastrukturu CoreWeave (+19 %) a Nebius Group (+21 %). Daří se však také akciím dodavatele optických technologií pro datová centra Lumentum Holdings (+7 %) či výrobci serverů Super Micro Computer (+13 %) po reportu výsledků hospodaření. Své výsledky zveřejnil také čínský gigant Tencent (-4 %) či kanadský softwarový holding Constellation Software (-5 %).
Společnost Lumentum Holdings zaznamenala ve 4Q FY 2026 tržby ve výši 1,01 mld. USD, což bylo více než dvojnásobek loňské hodnoty 480,7 mil. USD a nad odhady trhu 990 mil. USD. Očištěný zisk na akcii činil 3,23 USD při konsensus 2,97 USD. Trh také pozitivně hodnotí výhled pro 1Q FY 2027, ve kterém společnost očekává tržby v rozmezí 1,23 až 1,28 mld. USD oproti odhadu 1,15 mld. USD a očištěný zisk na akcii v rozmezí 4,05 až 4,35 USD je též nad odhady 3,58 USD. Analytici z Vital Knowledge poznamenali, že čísla i výhled jsou velmi dobré, ale očekávání už byla poměrně vysoká.
Index S&P 500 +0,25 % na 7747,61 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Informační technologie +1,2 % Zbytná spotřeba -1 % Reality +0,5 % Základní materiály -0,7 % Utility +0,5 % Komunikační služby -0,7 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Super Micro Computer (SMCI) +13 % Builders FirstSource (BLDR) -4,5 % Ciena Corp (CIEN) +9,9 % Charter Communications (CHTR) -4,2 % Sandisk Corp (SNDK) +7,8 % ServiceNow (NOW) -3,8 % Seagate Technology Holdings (STX) +7,5 % Tapestry (TPR) -3,7 % Lumentum Holdings (LITE) +7,0 % Zoetis (ZTS) -3,7 % Zdroj: Bloomberg
Zoetis (NYSE:ZTS) reported second-quarter revenue of $2.5 billion, flat on a reported basis and down 1% organically, as pressure in U.S. companion-animal categories offset growth in livestock, diagnostics and international markets. Adjusted net income was $781 million, down 2% organically, while adjusted diluted earnings per share rose 4% to $1.87, benefiting from a lower share count following share repurchases.
Chief Executive Officer Kristin Peck said the quarter fell short of the company’s expectations amid declining veterinary clinic visits, more selective spending by pet owners and greater promotional activity from competitors. Zoetis lowered its full-year outlook, now expecting organic operational revenue to decline 3% to 1% and adjusted net income to decline 9% to 5%.
Companion-Animal Demand and Competition Weigh on Results Peck said veterinary clinic visits continued a multiyear decline, while price increases in pet care have outpaced broader consumer inflation. Pet owners have become more selective in their spending, with clinic revenue shifting toward urgent and emergency care and premium preventative and chronic-care products facing pressure, she said.
Global companion-animal revenue was $1.7 billion, down 6% in the quarter. U.S. companion-animal revenue declined 11% to $1 billion, while international companion-animal revenue increased 5% to $664 million.
Key dermatology revenue fell 16% to $395 million globally. In the U.S., dermatology revenue declined 18% to $251 million, as canine pruritic clinic visits fell by more than 2%, according to Peck. Chief Financial Officer Wetteny Joseph said the company’s U.S. dermatology franchise retained about 86% in-clinic share during the quarter, though share declined 5 percentage points sequentially and 10 points from a year earlier.
Zoetis has begun using targeted promotions, rebates and other “growth-to-net” investments to protect volume and share rather than lowering list prices, Peck said. Those actions can include clinic-specific promotions, cross-portfolio bundles and point-of-sale discounts for pet owners.
“We are not changing the list price of our products,” Peck said in response to analyst questions. “What we’re talking about is investments in what, in the industry, they’ll call growth to net.”
The Simparica franchise generated $442 million in revenue, flat globally. Simparica Trio revenue fell 1% to $350 million, while Simparica revenue rose 4% to $91 million. International franchise growth was offset by U.S. pressure from softer flea, tick and heartworm visits, as well as a more competitive and promotional marketplace.
U.S. Simparica franchise revenue declined 6% to $308 million. Joseph said Simparica Trio held approximately 21% in-clinic share in U.S. oral parasiticides, nearly double its nearest competitor, and its puppy share was about 28%.
OA Pain Products Show Mixed Performance Global osteoarthritis pain monoclonal-antibody revenue was $147 million, down 3%. Canine OA pain products Librela and Lenivia produced $105 million in revenue, down 8%, while feline OA pain products Solensia and Portela generated $42 million, up 12%.
U.S. canine OA pain revenue declined 24% to $34 million, reflecting a strong prior-year comparison, softer clinic traffic and affordability pressures on premium therapies. International OA pain revenue increased 7% to $96 million, supported by early launches of long-acting Lenivia and Portela in the European Union and Canada.
Peck said Zoetis expects U.S. approval of long-acting Cytopoint later in 2026. The company also said early experience with Lenivia and Portela has been encouraging and that it expects further market expansion in the coming year.
Diagnostics and Livestock Provide Offsets Companion-animal diagnostics revenue rose 12% to $118 million, driven by adoption of technologies including Vetscan Imagyst and Vetscan OptiCell. During the quarter, Zoetis completed its acquisition of VitalRADS, a veterinary teleradiology services platform, expanding its capabilities in veterinary imaging interpretation.
Peck said commercial validation of Vetscan OmniMax, a multimodal chemistry platform that the company views as a potential blockbuster opportunity, remains expected by year-end.
Livestock revenue increased 11% to $731 million, with U.S. livestock revenue rising 23% to $222 million. Growth was driven by cattle and poultry, improved product supply and elevated U.S. demand for Dectomax and other injectable parasiticides in connection with the New World screwworm outbreak.
Joseph said several factors behind the U.S. livestock performance were transitory, including supply timing and screwworm-related demand. Zoetis expects U.S. livestock growth to moderate to the mid-single-digit range in the second half, while citing mid- to high-single-digit growth as a sustainable range for the business’ broader fundamentals.
Guidance Reduced as July Trends Show No Stabilization Zoetis now expects 2026 revenue of $9.12 billion to $9.32 billion. It projected adjusted net income of $2.57 billion to $2.62 billion, adjusted diluted EPS of $6.15 to $6.25, and reported diluted EPS of $5.55 to $5.65.
Joseph said the revised forecast incorporates sales trends through July, which had “not yet indicated market stabilization.” The upper end assumes competitive and pricing pressures remain contained, while the lower end contemplates accelerated pressure, greater dermatology and parasiticide share losses, continued July-like weakness and slower livestock uptake.
The company also cited an additional foreign-exchange headwind of roughly $60 million to $65 million to revenue and about $30 million to profit compared with its prior outlook.
Zoetis repurchased more than $550 million of shares during the quarter. Joseph said the company is maintaining investment in R&D and selected commercial priorities while pursuing cost and productivity actions; adjusted SG&A declined 4% operationally in the quarter.
Separately, Peck said Abhay Nayak was promoted to executive vice president and president of U.S. Commercial Operations. Jay Saccaro will join Zoetis on Aug. 17 as executive vice president, chief financial officer and chief operating officer, a newly created role overseeing finance as well as global manufacturing and supply. Joseph will remain a special advisor on financial matters until early 2027 to support the transition.
About Zoetis (NYSE:ZTS) Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Zoetis Inc. (NYSE:ZTS – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Monday after Piper Sandler lowered their price target on the stock from $90.00 to $80.00. Piper Sandler currently has a neutral rating on the stock. Zoetis traded as low as $71.45 and last traded at $71.8680, with a volume of 1784145 shares traded. The stock had previously closed at $72.66.
Several other equities analysts have also recently weighed in on the stock. William Blair reiterated a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. UBS Group cut their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Friday. Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Citigroup decreased their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Finally, TD Cowen dropped their price target on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research note on Tuesday, June 30th. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Zoetis presently has an average rating of “Hold” and a consensus price target of $110.92.
View Our Latest Research Report on Zoetis
Insider Activity at Zoetis In other news, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Paul Bisaro acquired 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.22% of the company’s stock.
Key Zoetis News Here are the key news stories impacting Zoetis this week:
Positive Sentiment: Zoetis exceeded second-quarter earnings expectations, reporting adjusted EPS of $1.87 versus the $1.85 consensus estimate. Its full-year 2026 EPS guidance of $6.15–$6.25 also provides an earnings framework for investors. Zoetis Earnings Call Reveals Growth Amid Headwinds Positive Sentiment: JPMorgan lowered its Zoetis price target to $115, but the target remains substantially above the stock’s recent trading level, suggesting the firm still sees potential upside. JPMorgan Chase Cuts Zoetis Price Target Neutral Sentiment: Piper Sandler cut its target from $90 to $80 and moved to a neutral rating. Although the revised target implies approximately 7% upside, the downgrade signals reduced conviction in Zoetis’s near-term performance. Piper Sandler Lowers Zoetis Price Target Neutral Sentiment: Market commentary is focused on whether Wall Street remains bullish or bearish, with the debate centered on Zoetis’s valuation, growth outlook and ability to overcome industry headwinds. Zoetis Stock: Is Wall Street Bullish or Bearish? Negative Sentiment: Second-quarter revenue of $2.47 billion fell short of the $2.50 billion consensus and declined slightly year over year. Coverage also highlights competitive pressures and cautious guidance, weighing on expectations for renewed growth. ZTS Q2 Deep Dive Negative Sentiment: Zoetis is undergoing a finance leadership transition, with the incoming CFO also taking on COO responsibilities. Investors may view the expanded role as a sign of an effort to improve execution during a challenging period. Boards Expand CFO Mandates Negative Sentiment: Recent analyses ask what went wrong after Zoetis was previously viewed as a high-quality growth company, while an investment-manager letter noted underperformance relative to its benchmark. This reinforces concerns about slowing momentum and investor confidence. Zoetis Looked Like a Winner: What Went Wrong? Institutional Inflows and Outflows Several hedge funds have recently bought and sold shares of ZTS. J. Stern & Co. LLP boosted its stake in shares of Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares during the period. Norges Bank purchased a new stake in shares of Zoetis during the fourth quarter worth about $734,425,000. Vanguard Group Inc. raised its stake in Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares during the period. Flossbach Von Storch SE bought a new stake in Zoetis during the 2nd quarter valued at approximately $302,601,000. Finally, BlackRock Inc. lifted its holdings in Zoetis by 10.8% in the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after purchasing an additional 3,845,869 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.
Zoetis Trading Up 2.7% The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The company has a market capitalization of $31.28 billion, a PE ratio of 12.29, a PEG ratio of 1.21 and a beta of 0.73. The stock has a fifty day moving average of $76.60 and a 200 day moving average of $100.24.
Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the previous year, the company earned $1.76 EPS. The business’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.43 earnings per share for the current fiscal year.
Zoetis Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is 34.93%.
About Zoetis (Get Free Report)
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Articles Five stocks we like better than Zoetis SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat 3 Dividend Champion Utilities for a Market That Can’t Sit Still These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI First Solar’s Profit Engine Faces a New Policy Test in Washington Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEWestwater Resources Sees Unusually High Options Volume (NASDAQ:WWR)
NEXT HEADLINE »Dai Nippon Printing (OTCMKTS:DNPLY) Shares Gap Up on Better-Than-Expected Earnings
Which Pet Stock Should Get Your Tail Wagging in 2024?Zoetis NYSE: ZTS reported second-quarter revenue of $2.5 billion, flat on a reported basis and down 1% organically, as pressure in U.S. companion-animal categories offset growth in livestock, diagnostics and international markets. Adjusted net income was $781 million, down 2% organically, while adjusted diluted earnings per share rose 4% to $1.87, benefiting from a lower share count following share repurchases.
Chief Executive Officer Kristin Peck said the quarter fell short of the company’s expectations amid declining veterinary clinic visits, more selective spending by pet owners and greater promotional activity from competitors. Zoetis lowered its full-year outlook, now expecting organic operational revenue to decline 3% to 1% and adjusted net income to decline 9% to 5%.
Get Zoetis alerts:
Companion-Animal Demand and Competition Weigh on Results MarketBeat Week in Review – 07/31 - 08/04Peck said veterinary clinic visits continued a multiyear decline, while price increases in pet care have outpaced broader consumer inflation. Pet owners have become more selective in their spending, with clinic revenue shifting toward urgent and emergency care and premium preventative and chronic-care products facing pressure, she said.
Global companion-animal revenue was $1.7 billion, down 6% in the quarter. U.S. companion-animal revenue declined 11% to $1 billion, while international companion-animal revenue increased 5% to $664 million.
Rising Dividend Make Zoetis a Doggone WinnerKey dermatology revenue fell 16% to $395 million globally. In the U.S., dermatology revenue declined 18% to $251 million, as canine pruritic clinic visits fell by more than 2%, according to Peck. Chief Financial Officer Wetteny Joseph said the company’s U.S. dermatology franchise retained about 86% in-clinic share during the quarter, though share declined 5 percentage points sequentially and 10 points from a year earlier.
Zoetis has begun using targeted promotions, rebates and other “growth-to-net” investments to protect volume and share rather than lowering list prices, Peck said. Those actions can include clinic-specific promotions, cross-portfolio bundles and point-of-sale discounts for pet owners.
“We are not changing the list price of our products,” Peck said in response to analyst questions. “What we’re talking about is investments in what, in the industry, they’ll call growth to net.”
The Simparica franchise generated $442 million in revenue, flat globally. Simparica Trio revenue fell 1% to $350 million, while Simparica revenue rose 4% to $91 million. International franchise growth was offset by U.S. pressure from softer flea, tick and heartworm visits, as well as a more competitive and promotional marketplace.
U.S. Simparica franchise revenue declined 6% to $308 million. Joseph said Simparica Trio held approximately 21% in-clinic share in U.S. oral parasiticides, nearly double its nearest competitor, and its puppy share was about 28%.
OA Pain Products Show Mixed Performance Global osteoarthritis pain monoclonal-antibody revenue was $147 million, down 3%. Canine OA pain products Librela and Lenivia produced $105 million in revenue, down 8%, while feline OA pain products Solensia and Portela generated $42 million, up 12%.
U.S. canine OA pain revenue declined 24% to $34 million, reflecting a strong prior-year comparison, softer clinic traffic and affordability pressures on premium therapies. International OA pain revenue increased 7% to $96 million, supported by early launches of long-acting Lenivia and Portela in the European Union and Canada.
Peck said Zoetis expects U.S. approval of long-acting Cytopoint later in 2026. The company also said early experience with Lenivia and Portela has been encouraging and that it expects further market expansion in the coming year.
Diagnostics and Livestock Provide Offsets Companion-animal diagnostics revenue rose 12% to $118 million, driven by adoption of technologies including Vetscan Imagyst and Vetscan OptiCell. During the quarter, Zoetis completed its acquisition of VitalRADS, a veterinary teleradiology services platform, expanding its capabilities in veterinary imaging interpretation.
Peck said commercial validation of Vetscan OmniMax, a multimodal chemistry platform that the company views as a potential blockbuster opportunity, remains expected by year-end.
Livestock revenue increased 11% to $731 million, with U.S. livestock revenue rising 23% to $222 million. Growth was driven by cattle and poultry, improved product supply and elevated U.S. demand for Dectomax and other injectable parasiticides in connection with the New World screwworm outbreak.
Joseph said several factors behind the U.S. livestock performance were transitory, including supply timing and screwworm-related demand. Zoetis expects U.S. livestock growth to moderate to the mid-single-digit range in the second half, while citing mid- to high-single-digit growth as a sustainable range for the business’ broader fundamentals.
Guidance Reduced as July Trends Show No Stabilization Zoetis now expects 2026 revenue of $9.12 billion to $9.32 billion. It projected adjusted net income of $2.57 billion to $2.62 billion, adjusted diluted EPS of $6.15 to $6.25, and reported diluted EPS of $5.55 to $5.65.
Joseph said the revised forecast incorporates sales trends through July, which had “not yet indicated market stabilization.” The upper end assumes competitive and pricing pressures remain contained, while the lower end contemplates accelerated pressure, greater dermatology and parasiticide share losses, continued July-like weakness and slower livestock uptake.
The company also cited an additional foreign-exchange headwind of roughly $60 million to $65 million to revenue and about $30 million to profit compared with its prior outlook.
Zoetis repurchased more than $550 million of shares during the quarter. Joseph said the company is maintaining investment in R&D and selected commercial priorities while pursuing cost and productivity actions; adjusted SG&A declined 4% operationally in the quarter.
Separately, Peck said Abhay Nayak was promoted to executive vice president and president of U.S. Commercial Operations. Jay Saccaro will join Zoetis on Aug. 17 as executive vice president, chief financial officer and chief operating officer, a newly created role overseeing finance as well as global manufacturing and supply. Joseph will remain a special advisor on financial matters until early 2027 to support the transition.
About Zoetis (NYSE:ZTS)Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Zoetis Right Now?Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Key Takeaways Zoetis' global Companion Animal revenues fell 6% organically, while U.S. Companion Animal declined 11%.ZTS cut 2026 revenue guidance to $9.12B-$9.32B as July trends showed no market stabilization.Zoetis is using targeted rebates, promotions and bundles to defend volume and share without broad price cuts. Zoetis Inc. (ZTS - Free Report) used its second-quarter 2026 earnings call to reset expectations for 2026 as weaker veterinary clinic traffic, pet-owner price sensitivity and heavier competition pressured major Companion Animal franchises.
CEO Kristin Peck said management is not assuming the market becomes easier soon. The response centers on targeted promotions, sharper commercial execution, cost discipline and continued investment in innovation.
ZTS Faces Tougher Companion Animal ConditionsCEO Kristin Peck said pressure intensified in the second quarter, particularly in Dermatology and U.S. parasiticides. Global Companion Animal revenues fell 6% on an organic operational basis, while U.S. Companion Animal declined 11%.
CFO Wetteny Joseph said Key Dermatology revenues fell 16%, with Apoquel facing softer demand and stronger promotional competition. The Simparica franchise was flat globally as international growth offset U.S. weakness.
ZTS’ second-quarter 2026 adjusted earnings of $1.87 per share exceeded the Zacks Consensus Estimate of $1.84. However, revenues of $2.47 billion missed the Zacks Consensus Estimate of $2.49 billion by 0.90%.
Zoetis Cuts Its 2026 OutlookCFO Wetteny Joseph revised full-year revenue guidance to $9.12 billion to $9.32 billion, implying an organic operational decline of 3% to 1%. Adjusted diluted earnings are now expected at $6.15 to $6.25.
Adjusted net income is projected at $2.57 billion to $2.62 billion, down 9% to 5% organically. CFO Wetteny Joseph said management incorporated July trends, which had not shown market stabilization.
CFO Wetteny Joseph said the high end assumes contained pricing and competitive pressure, manageable share losses in Dermatology and parasiticides, and continued strength in Livestock and Diagnostics. The low end assumes worsening competition, continued July weakness and slower Livestock uptake.
ZTS Uses Promotions to Defend ShareA Morgan Stanley analyst pressed management on pricing. CEO Kristin Peck said Zoetis is avoiding broad list-price cuts and instead using targeted gross-to-net investments, including rebates, promotions, cross-portfolio bundles and point-of-sale support.
A William Blair analyst asked about the margin implications. CEO Kristin Peck reiterated that these actions are intended to protect volume and share while preserving the longer-term value of the franchises.
CFO Wetteny Joseph later told a Stifel analyst that full-year price realization could range from flat to negative 1%, and potentially negative 2% near the low end of guidance, depending on competitive responses.
Zoetis Leans on Livestock and DiagnosticsCEO Kristin Peck highlighted diversification as an important counterweight. Livestock revenue grew 11% organically, while Companion Animal Diagnostics increased 12%.
CFO Wetteny Joseph said U.S. Livestock rose 23%, helped by cattle demand, supply timing and New World screwworm-related demand. He said some Q2 drivers were transitory and expects second-half U.S. Livestock growth to moderate.
CEO Kristin Peck also pointed to Diagnostics as a growth platform. Zoetis completed the VitalRADS acquisition and continued developing Vetscan OmniMax, with commercial validation still expected by year-end.
ZTS Keeps Innovation and Costs in FocusCEO Kristin Peck said Zoetis continues to advance a pipeline containing more than 12 potential blockbusters, including opportunities in chronic kidney disease, oncology, cardiology, anxiety and obesity.
The company is also expanding its OA pain portfolio with Lenivia and Portela in Canada and Europe. CEO Kristin Peck said early experience supported broader launches and reinforced management’s confidence in the category.
CFO Wetteny Joseph said adjusted SG&A declined 4% operationally as cost actions took hold, while adjusted R&D rose 4%. Zoetis also repurchased more than $550 million of shares during the quarter.
Zoetis Reshapes Leadership for ExecutionCEO Kristin Peck framed leadership changes as part of the push for faster execution. Abhay Nayak was promoted to lead U.S. Commercial Operations, where performance has been under pressure.
Jay Saccaro is joining as executive vice president, CFO and COO, combining finance with oversight of global manufacturing and supply. CEO Kristin Peck said the new structure is intended to improve decision-making and connectivity across operations.
Management’s tone remained cautious on the near-term market but firm on its priorities: defend share, control costs, support innovation and use portfolio diversification to navigate weaker Companion Animal demand.
ZTS Zacks Signals Show Conflicting FactorsZTS carries a Zacks Rank #4 (Sell) at present. Its Value Score of A, Momentum Score of A and VGM Score of B are favorable Style Scores, while the Growth Score of D is weaker.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Under the Zacks framework, favorable Style Scores are designed to complement top Zacks Rank #1 or 2 (Buy) stocks, while a Zacks Rank #4 indicates an unfavorable estimate-revision backdrop. The Zacks Rank can change as analysts revise estimates following the latest results.
Saccaro’s Appointment is Effective August 17, 2026; Wetteny Joseph to Serve as a Special Advisor to the CEO on Financial Matters Until Early 2027
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the appointment of James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. In this newly created role, Mr. Saccaro will lead Zoetis’ global finance function, shaping capital allocation, financial strategy, reporting and controls, and investor engagement and oversee Global Manufacturing and Supply to drive operational execution and performance. With Mr. Saccaro’s appointment, Wetteny Joseph will transition to an advisory role effective August 17, 2026. Mr. Joseph has agreed to remain with the company as a Special Advisor to the CEO on financial matters until early 2027 to facilitate a smooth transition.
Mr. Saccaro joins Zoetis with extensive executive leadership experience at large-scale life sciences companies. He most recently served as Vice President and CFO at GE HealthCare, where he led key initiatives for the newly established public company, including designing processes and approaches across finance, accounting, new product planning, R&D prioritization, and capital allocation, and overseeing the Information Technology function. Previously, Mr. Saccaro spent over two decades at Baxter International Inc., where he held positions of increasing responsibility, culminating in his role as Executive Vice President and CFO for eight years. In that role, he oversaw all aspects of the company’s finance and information technology functions and led a number of high-impact enterprise initiatives, including a margin and cash flow improvement plan following the company's successful spin-off of Baxalta. Mr. Saccaro led business development for Baxter’s $5 billion Medication Delivery unit and played a key role in major M&A.
“We are excited to welcome Jay to Zoetis as we prepare for our next wave of innovation-driven growth,” said Kristin Peck, Chief Executive Officer of Zoetis. “Jay brings a unique combination of skills to this newly created leadership position. He is a seasoned finance executive with 12 years of CFO experience at some of the world's leading healthcare companies and has proven expertise in successfully developing and executing company-wide strategic initiatives. Jay’s track record of designing financial frameworks that balance R&D investment with operational rigor and efficiency will be a significant asset as we sharpen our competitive edge and invest in our future growth platforms. In this expanded role, Jay will also continue to strengthen our global manufacturing and supply operations, enhancing supply chain and distribution performance, and driving greater operational excellence and agility. I look forward to partnering with Jay to build on our industry leadership and deliver sustainable growth and long-term value for shareholders.”
“I am thrilled to join the world’s leading animal health company,” said Mr. Saccaro. “From the company’s deep innovation pipeline to its products that have built and defined categories in the industry, Zoetis is an exceptional business grounded in a deep commitment to setting new standards for the future of animal care. There is tremendous runway to build on that legacy, and alongside Kristin, the leadership team and Zoetis’ talented colleagues, I’m eager to help unlock the opportunities ahead and drive sustainable value creation.”
Ms. Peck added, “On behalf of the Board of Directors and the entire Zoetis team, I thank Wetteny for his strong leadership, partnership, and many important contributions since joining the company five years ago. During his time with Zoetis, Wetteny has helped guide the company through a period of significant investment, change, and growth. We are grateful for his support through this transition and wish him all the best in his next chapter.”
“I am honored to have served as CFO of Zoetis and proud of our team’s accomplishments during my time with the company,” said Mr. Joseph. “I remain confident in Zoetis’ strategy, people and long-term opportunities. Zoetis remains strongly positioned to continue innovating and leading the animal health industry, and I look forward to watching its success for years to come.”
About Jay Saccaro
James (Jay) Saccaro is an accomplished executive with extensive leadership experience across global healthcare and life sciences organizations. He joins Zoetis from GE HealthCare, where he served as Vice President and Chief Financial Officer since 2023, leading the company’s finance, information technology, strategy and business development functions. Prior to GE HealthCare, Mr. Saccaro served as Executive Vice President and CFO at Baxter International Inc. from 2015 to 2023, where he played a key role in leading the company’s post-spin transformation, margin improvement initiatives and capital structure optimization. Prior to rejoining Baxter, Mr. Saccaro was Senior Vice President and CFO at Hill-Rom Corporation. He had previously served as the Corporate Vice President and Treasurer of Baxter from 2011 to 2013. Mr. Saccaro originally joined Baxter in 2002 as manager of strategy for the BioScience business, and over the years assumed positions of increasing responsibility, including vice president of financial planning and vice president of finance for the company’s operations in Europe, Middle East and Africa. He began his career in strategic planning at The Walt Disney Company.
Mr. Saccaro received a bachelor’s degree in economics and master’s degree in engineering-economic systems from Stanford University.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
Zoetis Inc. (NYSE:ZTS) reported second-quarter adjusted earnings of $1.87 per share, beating the consensus of $1.86.
The animal health company reported sales of $2.468 billion, missing the consensus of $2.502 billion. Revenue was flat year over year, decreasing 1% on an organic operational basis.
Zoetis Sees Softer Companion Animal Demand And Rising Competition"Second quarter results reflected a more pressured Companion Animal market, as lower clinic visits and pet owner price sensitivity reduced demand across parts of our portfolio and heightened competition in key categories," said Kristin Peck, CEO of Zoetis.
Read Next
"We are adapting our commercial strategy to the marketplace in front of us, deploying targeted investments, accelerating innovation, and pursuing business development to strengthen our position in areas aligned with the future of animal health," Peck commented.
The company, in its earnings call, said it faces competitive pressures, particularly in the dermatology and parasiticides sectors, with new entrants using aggressive pricing strategies.
The company also said it is moving with urgency as we navigate the current environment.
U.S. Companion Animal Sales Decline While Livestock Business StrengthensRevenue in the U.S. segment reached $1.3 billion, decreasing 7%. Companion animal product sales decreased 11% due to continued softer end-market demand.
The company’s key dermatology franchise and Simparica Trio faced persistent macro-driven price sensitivity and heightened competitive pressure.
Generic competition also impacted Cerenia and Convenia brands, as well as lower sales of Librela.
U.S. livestock product sales increased 23%, supported by strength across cattle and poultry.
Cattle performance was underpinned by favorable producer economics in beef cattle and supply timing. Poultry performance benefited from increased vaccine sales tied to disease outbreak activity.
Cuts 2026 Guidance As Market Headwinds PersistZoetis updated its 2026 outlook to reflect the headwinds expected to continue in the near term.
The company lowered fiscal 2026 adjusted earnings guidance from $6.85-$7.00 per share to $6.15-$6.25, compared with consensus of $6.88.
Zoetis also cut its 2026 sales guidance from $9.680 billion-$9.96 billion to $9.12 billion-$9.32 billion, compared to the consensus of $9.726 billion.
Management TransitionOn Thursday, Zoetis appointed James (Jay) Saccaro as Executive Vice President, CFO and COO, effective August 17.
With Saccaro’s appointment, Wetteny Joseph will transition to an advisory role.
ZTS Price Action: Zoetis shares were up 3.84% at $77.25 at the time of publication on Thursday, according to Benzinga Pro data.
Read Next
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Key Takeaways ZTS Q2 EPS beat estimates. Revenues were flat year over year and slightly missed expectations.ZTS now expects 2026 revenues of $9.12B-$9.32B and adjusted EPS of $6.15-$6.25, both down from prior outlook.Zoetis faced weaker U.S. companion animal sales, while international and U.S. livestock sales grew. Zoetis, Inc. (ZTS - Free Report) delivered second-quarter 2026 adjusted earnings (excluding one-time items) of $1.87 per share, which beat the Zacks Consensus Estimate of $1.84. In the year-ago quarter, the company had delivered adjusted earnings of $1.76 per share.
Total revenues were flat year over year at $2.47 billion in the second quarter and marginally missed the Zacks Consensus Estimate of $2.49 billion.
Year to date, shares of Zoetis have plunged 40% compared with the industry’s decline of 3.7%.
Image Source: Zacks Investment Research
ZTS’ Q2 Results in DetailZoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments — the United States and International.
Revenues from the U.S. segment decreased 7% year over year to $1.30 billion in the reported quarter, missing the Zacks Consensus Estimate of $1.33 billion.
Sales of companion animal products in the U.S. region declined 11% year over year to $1.04 billion, owing to softer end-market demand and an increasingly competitive landscape. Zoetis’ key dermatology franchise and Simparica Trio faced heightened competitive pressure and persistent macroeconomic-driven price sensitivity. Also, generic competition for the Convenia and Cerenia brands, as well as lower sales of ZTS’ monoclonal antibody product for osteoarthritis (OA) pain, Librela, for dogs, resulted in the decline.
Sales of livestock products in the United States increased 23% in the quarter to $222 million. The increase was mainly due to broad-based strength across cattle and poultry products.
Revenues in the International segment increased 8% year over year on a reported basis and 6% on an operational basis to $1.17 billion, beating the Zacks Consensus Estimate of $1.14 billion.
Ex-U.S. sales of companion animal products rose 8% on a reported basis and 5% operationally to $664 million, driven by growth in the parasiticides portfolio, including Simparica Trio, along with contributions from Revolution and Stronghold. Growth was also supported by companion animal diagnostics and the OA pain portfolio, following the launches of Lenivia and Portela.
Livestock product sales increased 8% year over year on a reported basis and 6% operationally to $509 million, driven by growth in cattle and poultry.
ZTS’ 2026 GuidanceZoetis lowered its revenue and earnings outlook for 2026.
The company now expects revenues to be in the range of $9.12 billion and $9.32 billion, reflecting an expected operational growth of negative 1-3%.
Previously, the company projected revenues between $9.68 billion and $9.96 billion, representing an expected operational growth of 2-5%.
Adjusted earnings are now expected in the range of $6.15-$6.25 per share in 2026, compared with the previous expectation of $6.85-$7.00 per share.
ZTS’ Zacks Rank and Stocks to ConsiderZoetis currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Repligen (RGEN - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 3.4% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 158.4% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.
Zoetis Inc. (ZTS) Q2 2026 Earnings Call August 6, 2026 8:30 AM EDT
Company Participants
Steven Frank - Vice President of Investor Relations
Kristin Peck - CEO & Director
Wetteny Joseph - Executive VP & CFO
Conference Call Participants
Erin Wilson Wright - Morgan Stanley, Research Division
Brandon Vazquez - William Blair & Company L.L.C., Research Division
Michael Ryskin - BofA Securities, Research Division
David Westenberg - Piper Sandler & Co., Research Division
Christopher Schott - JPMorgan Chase & Co, Research Division
Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division
Daniel Grosslight - Citigroup Inc., Research Division
Presentation
Operator
Welcome to the Second Quarter 2026 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis. The presentation materials and additional financial tables are currently posted on the Investor Relations section of zoetis.com.
The presentation slides can be managed by you, the viewer, and will not be forwarded automatically. In addition, a replay of this call will be available approximately 2 hours after the conclusion of this call via dial-in or on the Investor Relations section of zoetis.com. [Operator Instructions] The floor will be open for you questions following the presentation. [Operator Instructions]
It is now my pleasure to turn the call over to Steve Frank. Steve, you may begin.
Steven Frank
Vice President of Investor Relations
Thank you, operator. Good morning, everyone, and welcome to the Zoetis Second Quarter 2026 Earnings Call. I am joined today by Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Chief Financial Officer. This morning, we issued a press release announcing our financial results.
Before we begin, I would like to remind you that the release and corresponding earnings presentation, which we will reference during this call, are available on the Investor Relations section of our website and that many
Zoetis (ZTS - Free Report) came out with quarterly earnings of $1.87 per share, beating the Zacks Consensus Estimate of $1.84 per share. This compares to earnings of $1.76 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +1.63%. A quarter ago, it was expected that this animal health company would post earnings of $1.61 per share when it actually produced earnings of $1.53, delivering a surprise of -4.97%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Zoetis, which belongs to the Zacks Medical - Drugs industry, posted revenues of $2.47 billion for the quarter ended June 2026, missing the Zacks Consensus Estimate by 0.95%. This compares to year-ago revenues of $2.46 billion. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Zoetis shares have lost about 40.9% since the beginning of the year versus the S&P 500's gain of 12.8%.
What's Next for Zoetis?While Zoetis has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Zoetis was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.86 on $2.51 billion in revenues for the coming quarter and $6.89 on $9.72 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Vivos Therapeutics, Inc. (VVOS - Free Report) , has yet to report results for the quarter ended June 2026.
This company is expected to post quarterly loss of $0.42 per share in its upcoming report, which represents a year-over-year change of +23.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Vivos Therapeutics, Inc.'s revenues are expected to be $5.43 million, up 42.2% from the year-ago quarter.
Zoetis (ZTS - Free Report) reported $2.47 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 0.3%. EPS of $1.87 for the same period compares to $1.76 a year ago.
The reported revenue represents a surprise of -0.95% over the Zacks Consensus Estimate of $2.49 billion. With the consensus EPS estimate being $1.84, the EPS surprise was +1.63%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Zoetis performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Geographic Revenues- U.S.: $1.27 billion versus $1.33 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -6.6% change.Geographic Revenues- International Revenue: $1.17 billion versus $1.14 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.6% change.Geographic Revenues- International- Livestock: $509 million versus $491.12 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +11.1% change.Geographic Revenues- U.S.- Livestock: $222 million compared to the $191.1 million average estimate based on three analysts. The reported number represents a change of +23.3% year over year.Geographic Revenues- International- Companion Animal: $664 million versus $651.08 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8.5% change.Geographic Revenues- U.S.- Companion Animal: $1.04 billion compared to the $1.14 billion average estimate based on three analysts. The reported number represents a change of -11.2% year over year.Revenues- Livestock: $731 million versus $678.9 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.6% change.Revenues- Contract Manufacturing & Human Health: $29 million versus the three-analyst average estimate of $35.13 million. The reported number represents a year-over-year change of -14.7%.Revenues- Companion Animal: $1.71 billion versus the three-analyst average estimate of $1.77 billion. The reported number represents a year-over-year change of -4.5%.View all Key Company Metrics for Zoetis here>>>
Shares of Zoetis have returned -1% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the second quarter of 2026.
The company reported revenue of $2.5 billion for the second quarter of 2026, flat compared with the second quarter of 2025, decreasing 1% on an organic operational1 basis. Net income for the second quarter of 2026 was $691 million, or $1.65 per diluted share, decreasing 5% and growing 1%, respectively, on a reported basis.
Adjusted net income2 for the second quarter of 2026 was $781 million, or $1.87 per diluted share, decreasing 1% and increasing 5%, respectively, on a reported basis, decreasing 2% and increasing 4%, respectively, on an organic operational basis. Adjusted net income for the second quarter of 2026 excludes the net impact of $90 million for purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.
"Second quarter results reflected a more pressured Companion Animal market, as lower clinic visits and pet owner price sensitivity reduced demand across parts of our portfolio and heightened competition in key categories," said Kristin Peck, Chief Executive Officer of Zoetis. "At the same time, these dynamics reinforce the enduring attractiveness of the markets Zoetis has helped define and advance. We are adapting our commercial strategy to the marketplace in front of us, deploying targeted investments, accelerating innovation, and pursuing business development to strengthen our position in areas aligned with the future of animal health. We also continue to benefit from the breadth of our diversified portfolio, including strength in Livestock and Diagnostics. As we advance our robust pipeline, including more than 12 potential blockbusters over the coming years, we are acting with urgency and remain confident in the long-term fundamentals of animal health and in Zoetis' ability to compete, lead, and create shareholder value."
SEGMENT HIGHLIGHTS
Zoetis organizes and manages its commercial operations across two segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock, tailored to local trends and customer needs. In the second quarter of 2026:
Revenue in the U.S. segment totaled $1.3 billion, decreasing 7% on both a reported and an organic operational basis relative to the second quarter of 2025. Companion animal product sales decreased 11% due to continued softer end-market demand. The company's key dermatology franchise and Simparica Trio® faced persistent macro-driven price sensitivity and heightened competitive pressure. Also contributing to the decline was the impact of generic competition on the Cerenia® and Convenia® brands, as well as lower sales of Librela®. Sales of livestock products increased 23% on both a reported and organic operational basis in the quarter, supported by strength across cattle and poultry. Cattle performance was underpinned by favorable producer economics in beef cattle and supply timing. Poultry performance benefited from increased vaccine sales tied to disease outbreak activity. Revenue in the International segment was $1.2 billion, increasing 8% on a reported basis and 6% on an organic operational basis compared with the second quarter of 2025. Companion animal product sales grew 8% on a reported basis and 5% on an organic operational basis, led by the company's parasiticides portfolio, including Simparica Trio, along with contributions from Revolution® and Stronghold®. Also contributing to growth was companion animal diagnostics, as well as osteoarthritis (OA) pain with the launch of Lenivia® and Portela™, the company's long-acting monoclonal antibody pain products that provide dogs and cats with up to three months of pain relief. These gains were partially offset by lower sales of key dermatology products as well as challenging market conditions impacting the broader portfolio. Sales of livestock products grew 8% on a reported basis and 6% on an organic operational basis, driven by growth in cattle and poultry. INVESTMENTS IN GROWTH
Zoetis continued to advance innovation across its diversified portfolio, including a pipeline with more than 12 potential blockbuster3 candidates in areas such as chronic kidney disease, oncology, cardiology, anxiety and obesity. During the quarter, the company advanced major-market approvals, expanded access to industry-leading treatments in new geographies, enhanced diagnostics capabilities, and delivered solutions to support customers facing emerging and transboundary infectious disease threats. Together, these efforts reflect Zoetis' focus on translating science, global scale and customer insights into solutions that improve the health of companion animals and livestock around the world.
Delivering on Commitment to Innovation
Zoetis is executing on its commitment to deliver a significant approval in a major market every year for the next several years. In July, the company received marketing authorization from the European Commission for Poulvac® Procerta® HVT-ND. This approval reinforces Zoetis’ focus on ensuring a stable and reliable protein supply, helping protect poultry production against Newcastle and Marek’s disease.
Lenivia and Portela, long-acting monoclonal antibody therapies providing dogs and cats with up to three months of OA pain relief from a single injection, launched in Canada and the EU and were approved in Great Britain. Lenivia was also approved in Switzerland.
Supporting Prevention and Treatment of New World Screwworm
With New World screwworm now confirmed in the United States, Zoetis has been well prepared to support customers’ prevention and treatment strategies. Dectomax®-CA1, the first parasite control product to receive FDA conditional approval for the prevention and treatment of New World screwworm myiasis in beef cattle, together with Dectomax®, received emergency use authorization in the U.S. for prevention of infestations in swine, sheep, deer, horses, lactating and dry dairy cows, and dairy replacement heifers. This response underscores Zoetis’ long-standing support for a One Health approach and its ability to deliver targeted solutions when disease threats affect animals, customers, and the broader food supply.
Additional approvals from the quarter include:
Vanguard® crLyme received a label update in the U.S. for effectiveness against subclinical arthritis caused by Borrelia burgdorferi, representing a significant pipeline acceleration. Bonqat®, an oral medication to help alleviate acute anxiety and fear associated with transportation and veterinary visits in cats, was approved in China. Synovex® One Grower gained an expanded label approval in the U.S. to increase the rate of weight gain in growing beef steers and heifers in dry lots or on pasture with insufficient forage. Suvaxyn® PRRS Needle-Free Microdose, a vaccine that helps prevent porcine reproductive and respiratory syndrome, was approved in the EU. This approval includes a needle free intramuscular administration claim and a new multidose presentation. Fostera® Gold PVC MH Flex, a vaccine to help prevent infection from Mycoplasma hyopneumoniae and Porcine circovirus, was approved in Japan. Accelerating Diagnostics Capabilities
In July, Zoetis completed the acquisition of VitalRADS, a veterinary teleradiology services platform. This milestone advances Zoetis’ strategic pursuit of opportunities that unlock new sources of growth by expanding its Global Diagnostics offering with around-the-clock access to board-certified veterinary specialists through a cloud-based teleradiology platform. The acquisition will extend Zoetis’ capabilities beyond in-vitro testing into veterinary imaging interpretation and advance its vision of a more complete end-to-end Virtual Reference Lab.
Zoetis also expanded the capabilities of Vetscan Opticell™, making it the first and only point of care hematology analyzer to offer cellular hemoglobin mean – previously available only in reference laboratories. This expansion adds greater diagnostic depth in clinics and delivers value to veterinary teams through time, cost, and space savings.
Together, these investments strengthen Zoetis’ diagnostics capabilities and reinforce the company’s differentiated position in animal health with scale across both diagnostics and therapeutics.
Advancing Sustainability in Animal Health for a Better Future
In June, Zoetis published its 2025 Sustainability Report, marking the completion of its initial Driven to Care aspirations set in 2021 and introducing the strategy’s next phase, with an even sharper focus across Communities, Animals and the Planet. The report also highlighted that the Zoetis Foundation fulfilled its commitment to distribute $35 million in grants from 2021 to 2025, helping strengthen the animal health ecosystem by advancing opportunities for veterinary professionals and livestock farmers.
FINANCIAL GUIDANCE
Zoetis is providing updated guidance based on the current operating environment.
Revenue of $9.120 billion to $9.320 billion (organic operational growth of (3)% to (1)%) Reported net income of $2.330 billion to $2.380 billion Adjusted net income of $2.570 billion to $2.620 billion (organic operational growth of (9)% to (5)%) Reported diluted EPS of $5.55 to $5.65 Adjusted diluted EPS of $6.15 to $6.25 This guidance reflects foreign exchange rates as of July 21, 2026. Additional details on guidance are included in the financial tables and will be discussed on the company's conference call.
WEBCAST & CONFERENCE CALL DETAILS
Zoetis will host a webcast and conference call today at 8:30 a.m. ET to review second quarter 2026 results, discuss financial guidance and respond to questions from financial analysts. The live webcast and corresponding slides can be accessed by visiting https://investor.zoetis.com/events-presentations. A replay of the webcast will be available following the event.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.
1 Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures.
2 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.
3 A blockbuster has annual sales of at least $100 million.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; expectations regarding competing products; expectations regarding financial impact of divestitures; disruptions in our global supply chain; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; foreign exchange rates, tax rates, tariffs, changes in tax regimes and laws and any changes thereto; possible impacts of the Fiscal Year Alignment; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share, operational results (which exclude the impact of foreign exchange) and organic operational results (which exclude the impact of foreign exchange and certain acquisitions and divestitures), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com.
Internet Posting of Information: We routinely post information that may be important to investors on the 'Investor Relations' section of our website at www.zoetis.com, as well as on LinkedIn, Facebook, X (formerly Twitter) and YouTube. We encourage investors and potential investors to consult our website regularly and to follow us on social media for company news and information.
ZTS-COR
ZTS-IR
ZTS-FIN
ZOETIS INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
(millions of dollars, except per share data)
Three Months Ended
Six Months Ended
June 30,
June 30,
2026
2025
% Change
2026
2025
% Change
Revenue
$
2,468
$
2,474
—
$
4,730
$
4,672
1
Costs and expenses:
Cost of sales
673
664
1
1,314
1,282
2
Selling, general and administrative expenses
592
614
(4
)
1,180
1,188
(1
)
Research and development expenses
173
166
4
353
328
8
Amortization of intangible assets
31
33
(6
)
62
65
(5
)
Restructuring charges and certain acquisition and divestiture-related costs
77
30
*
99
30
*
Interest expense, net of capitalized interest
61
53
15
123
107
15
Other (income)/deductions–net
(5
)
2
*
(25
)
(13
)
92
Income before provision for taxes on income
866
912
(5
)
1,624
1,685
(4
)
Provision for taxes on income
175
186
(6
)
332
357
(7
)
Net income before allocation to noncontrolling interests
691
726
(5
)
1,292
1,328
(3
)
Less: Net income/(loss) attributable to noncontrolling interests
—
—
*
—
—
*
Net income attributable to Zoetis Inc.
$
691
$
726
(5
)
$
1,292
$
1,328
(3
)
Earnings per share attributable to Zoetis—basic
$
1.65
$
1.63
1
$
3.08
$
2.98
3
Earnings per share attributable to Zoetis—diluted
$
1.65
$
1.63
1
$
3.08
$
2.97
4
Weighted-average shares used to calculate earnings per share
Basic
417.6
445.1
419.9
446.3
Diluted
417.7
445.5
420.1
446.7
* Calculation not meaningful.
ZOETIS INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars, except per share data)
Three Months Ended June 30, 2026
GAAP Reported
Purchase Accounting Adjustments
Acquisition and Divestiture- Related Costs(1)
Certain Significant Items(2)
Non-GAAP Adjusted(a)
Cost of sales
$
673
$
(1
)
$
—
$
(3
)
$
669
Gross profit
1,795
1
—
3
1,799
Selling, general and administrative expenses
592
(3
)
—
(3
)
586
Amortization of intangible assets
31
(26
)
—
—
5
Restructuring charges and certain acquisition and divestiture-related costs
77
—
(2
)
(75
)
—
Income before provision for taxes on income
866
30
2
81
979
Provision for taxes on income
175
6
—
17
198
Net income attributable to Zoetis
691
24
2
64
781
Earnings per common share attributable to Zoetis–diluted
1.65
0.06
—
0.16
1.87
Three Months Ended June 30, 2025
GAAP Reported
Purchase Accounting Adjustments
Acquisition and Divestiture- Related Costs(1)
Certain Significant Items(2)
Non-GAAP Adjusted(a)
Cost of sales
$
664
$
(1
)
$
—
$
(2
)
$
661
Gross profit
1,810
1
—
2
1,813
Selling, general and administrative expenses
614
(2
)
—
(9
)
603
Research and development expenses
166
(1
)
—
—
165
Amortization of intangible assets
33
(29
)
—
—
4
Restructuring charges and certain acquisition and divestiture-related costs
30
—
(1
)
(29
)
—
Other (income)/deductions–net
2
—
—
(8
)
(6
)
Income before provision for taxes on income
912
33
1
48
994
Provision for taxes on income
186
8
—
9
203
Net income attributable to Zoetis
726
25
1
39
791
Earnings per common share attributable to Zoetis–diluted
1.63
0.06
—
0.09
1.78
(a) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).
ZOETIS INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars, except per share data)
Six Months Ended June 30, 2026
GAAP Reported
Purchase Accounting Adjustments
Acquisition and Divestiture- Related Costs(1)
Certain Significant Items(2)
Non-GAAP Adjusted(a)
Cost of sales
$
1,314
$
(2
)
$
—
$
(5
)
$
1,307
Gross profit
3,416
2
—
5
3,423
Selling, general and administrative expenses
1,180
(2
)
—
(7
)
1,171
Research and development expenses
353
(1
)
—
—
352
Amortization of intangible assets
62
(53
)
—
—
9
Restructuring charges and certain acquisition and divestiture-related costs
99
—
(4
)
(95
)
—
Other (income)/deductions–net
(25
)
—
—
(1
)
(26
)
Income before provision for taxes on income
1,624
58
4
108
1,794
Provision for taxes on income
332
13
1
21
367
Net income attributable to Zoetis
1,292
45
3
87
1,427
Earnings per common share attributable to Zoetis–diluted
3.08
0.11
—
0.21
3.40
Six Months Ended June 30, 2025
GAAP Reported
Purchase Accounting Adjustments
Acquisition and Divestiture- Related Costs(1)
Certain Significant Items(2)
Non-GAAP Adjusted(a)
Cost of sales
$
1,282
$
(2
)
$
—
$
(2
)
$
1,278
Gross profit
3,390
2
—
2
3,394
Selling, general and administrative expenses
1,188
(5
)
—
(15
)
1,168
Research and development expenses
328
(1
)
—
—
327
Amortization of intangible assets
65
(57
)
—
—
8
Restructuring charges and certain acquisition and divestiture-related costs
30
—
(1
)
(29
)
—
Other (income)/deductions–net
(13
)
—
—
(8
)
(21
)
Income before provision for taxes on income
1,685
65
1
54
1,805
Provision for taxes on income
357
15
—
9
381
Net income attributable to Zoetis
1,328
50
1
45
1,424
Earnings per common share attributable to Zoetis–diluted
2.97
0.12
—
0.10
3.19
(a) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).
ZOETIS INC.
NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars)
(1) Acquisition and divestiture-related costs include the following:
Three Months Ended
Six Months Ended
June 30,
June 30,
2026
2025
2026
2025
Acquisition-related costs(a)
$
2
$
1
$
4
$
1
Total acquisition and divestiture-related costs—pre-tax
2
1
4
1
Income taxes(b)
—
—
1
—
Total acquisition and divestiture-related costs—net of tax
$
2
$
1
$
3
$
1
(a) Acquisition-related costs represent external, incremental costs that directly relate to transacting and integrating businesses, included in Restructuring charges and certain acquisition and divestiture-related costs.
(b) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.
(2) Certain significant items include the following:
Three Months Ended
Six Months Ended
June 30,
June 30,
2026
2025
2026
2025
Other restructuring charges and cost-reduction/productivity initiatives(a)
$
75
$
7
$
95
$
7
Business process transformation program(b)
6
11
11
18
Certain asset impairment charges(c)
—
27
—
27
Net loss on sale of business(d)
—
3
—
3
Other
—
—
2
(1
)
Total certain significant items—pre-tax
81
48
108
54
Income taxes(e)
17
9
21
9
Total certain significant items—net of tax
$
64
$
39
$
87
$
45
(a) For the three and six months ended June 30, 2026, primarily driven by employee termination costs under a comprehensive cost and productivity program, with the six-month period also reflecting employee termination costs from additional organizational structure refinements.
For the three and six months ended June 30, 2025, primarily consisted of employee termination costs related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site, included in Restructuring charges and certain acquisition and divestiture-related costs.
(b) Represents costs related to our multi-year business process transformation program, which includes the implementation of a new enterprise resource planning (ERP) system, related digital technology solutions and other related costs, included in Selling, general and administrative expenses and Cost of sales. This comprehensive program is a major global and cross-functional company-wide effort that we believe will transform how we work across our business and contribute to all of our strategic priorities. Due to the nature, scope and magnitude of this investment, these costs are incremental transformational costs that are far in excess of the historical normal level of spending to support operations and are not expected to recur in the foreseeable future.
(c) Represents certain asset impairment charges related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site, included in Restructuring charges and certain acquisition and divestiture-related costs, as well as charges related to our aquaculture product portfolio included in Other (income)/deductions–net.
(d) Represents a net loss related to the sale of our medicated feed additive product portfolio, certain water soluble products and related assets sold in 2024, included in Other (income)/deductions–net.
(e) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.
ZOETIS INC.
ADJUSTED SELECTED COSTS, EXPENSES AND INCOME(a)
(UNAUDITED)
(millions of dollars)
Three Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Operational(b)
Divestitures
Organic Operational(c)
Adjusted cost of sales
$
669
$
661
1
%
3
%
(2
)%
as a percent of revenue
27.1
%
26.7
%
NA
NA
NA
Adjusted SG&A expenses
586
603
(3
)%
1
%
(4
)%
Adjusted R&D expenses
173
165
5
%
1
%
4
%
Adjusted net income
781
791
(1
)%
1
%
(2
)%
—
%
(2
)%
Six Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Operational(b)
Divestitures
Organic Operational(c)
Adjusted cost of sales
$
1,307
$
1,278
2
%
6
%
(4
)%
as a percent of revenue
27.6
%
27.4
%
NA
NA
NA
Adjusted SG&A expenses
1,171
1,168
—
%
2
%
(2
)%
Adjusted R&D expenses
352
327
8
%
2
%
6
%
Adjusted net income
1,427
1,424
—
%
1
%
(1
)%
—
%
(1
)%
(a) Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net income (non-GAAP financial measures) are defined as the corresponding reported U.S. GAAP income statement line items excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items. The corresponding GAAP line items and reconciliations of reported to adjusted information are provided in Condensed Consolidated Statements of Income and Reconciliation of GAAP Reported to Non-GAAP Adjusted Information.
(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.
(c) Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures.
ZOETIS INC.
2026 GUIDANCE
Selected Line Items
(millions of dollars, except per share amounts)
Full Year 2026
as of August 6, 2026
Full Year 2026
as of May 7, 2026
(Prior Guidance)
Revenue
$9,120 to $9,320
$9,680 to $9,960
Organic operational results(a)
(3)% to (1)%
2% to 5%
Adjusted cost of sales as a percentage of revenue(b)
Approximately 29.0%
Approximately 28.5%
Adjusted SG&A expenses(b)
$2,330 to $2,380
$2,350 to $2,400
Adjusted R&D expenses(b)
$720 to $730
$735 to $745
Adjusted interest expense and other (income)/deductions-net(b)
Approximately $215
Approximately $215
Effective tax rate on adjusted income(b)
Approximately 20.5%
Approximately 20.5%
Adjusted diluted EPS(b)
$6.15 to $6.25
$6.85 to $7.00
Adjusted net income(b)
$2,570 to $2,620
$2,870 to $2,950
Organic operational results(a)(c)
(9)% to (5)%
2% to 6%
Certain significant items and acquisition and divestiture-related costs(d)
Approximately $150
Approximately $100
Reported diluted EPS
$5.55 to $5.65
$6.35 to $6.50
The guidance reflects foreign exchange rates as of July 21, 2026.
Reconciliations of 2026 reported guidance to 2026 adjusted guidance follows:
(millions of dollars, except per share amounts) Reported
Certain significant items and acquisition and divestiture-related costs(d)
Purchase accounting
Adjusted(b)
Cost of sales as a percentage of revenue
~ 29.2%
~ (0.2%)
~ 29.0%
SG&A expenses
$2,350 to $2,400
~ $(12)
~ $(8)
$2,330 to $2,380
R&D expenses
$722 to $732
~ $(2)
$720 to $730
Interest expense and other (income)/deductions-net
~ $215
~ $215
Effective tax rate
~ 20.6%
~ (0.1%)
~ 20.5%
Diluted EPS
$5.55 to $5.65
~ $0.38
~ $0.22
$6.15 to $6.25
Net income attributable to Zoetis
$2,330 to $2,380
~ $150
~ $90
$2,570 to $2,620
(a) Organic operational results (a non-GAAP financial measure) excludes the impact of foreign exchange and certain acquisitions and divestitures.
(b) Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. GAAP net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. Adjusted cost of sales, adjusted SG&A expenses, adjusted R&D expenses, and adjusted interest expense and other (income)/deductions-net are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.
(c) We do not provide a reconciliation of forward-looking non-GAAP adjusted net income operational results to the most directly comparable U.S. GAAP reported financial measure because we are unable to calculate with reasonable certainty the foreign exchange impact of unusual gains and losses, acquisition and divestiture-related expenses, potential future asset impairments and other certain significant items, without unreasonable effort. The foreign exchange impacts of these items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.
(d) Primarily includes certain nonrecurring costs related to acquisitions, divestitures and other charges.
ZOETIS INC.
CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES
(UNAUDITED)
(millions of dollars)
Three Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Operational(b)
Divestitures
Organic Operational(c)
Revenue:
Companion Animal
$
1,708
$
1,790
(5
)%
1
%
(6
)%
—
%
(6
)%
Livestock
731
651
12
%
2
%
10
%
(1
)%
11
%
Contract Manufacturing & Human Health
29
33
(12
)%
1
%
(13
)%
—
%
(13
)%
Total Revenue
$
2,468
$
2,474
—
%
2
%
(2
)%
(1
)%
(1
)%
U.S.:
Companion Animal
$
1,044
$
1,176
(11
)%
—
%
(11
)%
—
%
(11
)%
Livestock
222
180
23
%
—
%
23
%
—
%
23
%
Total U.S. Revenue
$
1,266
$
1,356
(7
)%
—
%
(7
)%
—
%
(7
)%
International:
Companion Animal
$
664
$
614
8
%
3
%
5
%
—
%
5
%
Livestock
509
471
8
%
4
%
4
%
(2
)%
6
%
Total International Revenue
$
1,173
$
1,085
8
%
3
%
5
%
(1
)%
6
%
Companion Animal:
Dogs and Cats
$
1,634
$
1,719
(5
)%
1
%
(6
)%
Horses
74
71
4
%
1
%
3
%
Total Companion Animal Revenue
$
1,708
$
1,790
(5
)%
1
%
(6
)%
Livestock:
Cattle
$
390
$
323
21
%
3
%
18
%
Swine
117
118
(1
)%
2
%
(3
)%
Poultry
115
104
11
%
1
%
10
%
Fish
83
81
2
%
4
%
(2
)%
Sheep and other
26
25
4
%
8
%
(4
)%
Total Livestock Revenue
$
731
$
651
12
%
2
%
10
%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.
(c) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures.
ZOETIS INC.
CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES
(UNAUDITED)
(millions of dollars)
Six Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Operational(b)
Divestitures
Organic Operational(c)
Revenue:
Companion Animal
$
3,227
$
3,331
(3
)%
2
%
(5
)%
—
%
(5
)%
Livestock
1,451
1,278
14
%
4
%
10
%
(1
)%
11
%
Contract Manufacturing & Human Health
52
63
(17
)%
1
%
(18
)%
—
%
(18
)%
Total Revenue
$
4,730
$
4,672
1
%
2
%
(1
)%
—
%
(1
)%
U.S.:
Companion Animal
$
1,909
$
2,149
(11
)%
—
%
(11
)%
—
%
(11
)%
Livestock
447
390
15
%
—
%
15
%
—
%
15
%
Total U.S. Revenue
$
2,356
$
2,539
(7
)%
—
%
(7
)%
—
%
(7
)%
International:
Companion Animal
$
1,318
$
1,182
12
%
6
%
6
%
—
%
6
%
Livestock
1,004
888
13
%
5
%
8
%
(2
)%
10
%
Total International Revenue
$
2,322
$
2,070
12
%
5
%
7
%
(1
)%
8
%
Companion Animal:
Dogs and Cats
$
3,077
$
3,196
(4
)%
2
%
(6
)%
Horses
150
135
11
%
3
%
8
%
Total Companion Animal Revenue
$
3,227
$
3,331
(3
)%
2
%
(5
)%
Livestock:
Cattle
$
782
$
664
18
%
4
%
14
%
Swine
240
223
8
%
4
%
4
%
Poultry
233
210
11
%
2
%
9
%
Fish
149
136
10
%
7
%
3
%
Sheep and other
47
45
4
%
7
%
(3
)%
Total Livestock Revenue
$
1,451
$
1,278
14
%
4
%
10
%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.
(c) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures.
ZOETIS INC.
CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS
(UNAUDITED)
(millions of dollars)
Three Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Divestitures
Organic Operational(a)
Total International
$
1,173
$
1,085
8
%
3
%
(1
)%
6
%
Australia
94
83
13
%
11
%
—
%
2
%
Brazil
103
93
11
%
11
%
—
%
—
%
Canada
72
71
1
%
—
%
(5
)%
6
%
Chile
34
34
—
%
—
%
—
%
—
%
China
62
67
(7
)%
7
%
—
%
(14
)%
France
40
42
(5
)%
3
%
—
%
(8
)%
Germany
69
57
21
%
2
%
—
%
19
%
Italy
40
37
8
%
1
%
—
%
7
%
Japan
41
43
(5
)%
(11
)%
—
%
6
%
Mexico
47
39
21
%
15
%
—
%
6
%
Spain
43
40
8
%
2
%
(1
)%
7
%
United Kingdom
72
81
(11
)%
(1
)%
(1
)%
(9
)%
Other developed markets
187
175
7
%
3
%
—
%
4
%
Other emerging markets
269
223
21
%
1
%
(1
)%
21
%
Six Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Divestitures
Organic Operational(a)
Total International
$
2,322
$
2,070
12
%
5
%
(1
)%
8
%
Australia
183
162
13
%
11
%
—
%
2
%
Brazil
193
174
11
%
11
%
—
%
—
%
Canada
145
141
3
%
3
%
(6
)%
6
%
Chile
72
69
4
%
2
%
—
%
2
%
China
125
122
2
%
5
%
—
%
(3
)%
France
77
81
(5
)%
6
%
—
%
(11
)%
Germany
128
112
14
%
6
%
—
%
8
%
Italy
79
67
18
%
8
%
(1
)%
11
%
Japan
76
75
1
%
(8
)%
—
%
9
%
Mexico
95
74
28
%
16
%
—
%
12
%
Spain
83
69
20
%
7
%
(1
)%
14
%
United Kingdom
150
155
(3
)%
3
%
(1
)%
(5
)%
Other developed markets
356
308
16
%
7
%
—
%
9
%
Other emerging markets
560
461
21
%
1
%
(1
)%
21
%
(a) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures.
ZOETIS INC.
SEGMENT(a) EARNINGS
(UNAUDITED)
(millions of dollars)
Three Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Operational(b)
U.S.:
Revenue
$
1,266
$
1,356
(7
)%
—
%
(7
)%
Cost of Sales
214
208
3
%
—
%
3
%
Gross Profit
1,052
1,148
(8
)%
—
%
(8
)%
Gross Margin
83.1
%
84.7
%
Operating Expenses
215
218
(1
)%
—
%
(1
)%
Other (income)/deductions-net
—
—
*
*
*
U.S. Earnings
$
837
$
930
(10
)%
—
%
(10
)%
International:
Revenue
$
1,173
$
1,085
8
%
3
%
5
%
Cost of Sales
340
321
6
%
4
%
2
%
Gross Profit
833
764
9
%
3
%
6
%
Gross Margin
71.0
%
70.4
%
Operating Expenses
172
171
1
%
3
%
(2
)%
Other (income)/deductions-net
—
1
*
*
*
International Earnings
$
661
$
592
12
%
4
%
8
%
Total Reportable Segments
$
1,498
$
1,522
(2
)%
1
%
(3
)%
Other business activities(c)
(135
)
(129
)
5
%
Reconciling Items:
Corporate(d)
(315
)
(324
)
(3
)%
Purchase accounting adjustments(e)
(30
)
(33
)
(9
)%
Acquisition and divestiture-related costs(f)
(2
)
(1
)
*
Certain significant items(g)
(81
)
(48
)
69
%
Other unallocated(h)
(69
)
(75
)
(8
)%
Total Earnings(i)
$
866
$
912
(5
)%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.
(c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.
(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.
(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.
(f) Acquisition and divestiture-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as costs associated with divesting and disintegrating a portion of our business.
(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition, costs related to our business process transformation program, as well as the impact of divestiture gains and losses.
(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.
(i) Defined as income before provision for taxes on income.
* Calculation not meaningful.
ZOETIS INC.
SEGMENT(a) EARNINGS
(UNAUDITED)
(millions of dollars)
Six Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Operational(b)
U.S.:
Revenue
$
2,356
$
2,539
(7
)%
—
%
(7
)%
Cost of Sales
408
407
—
%
—
%
—
%
Gross Profit
1,948
2,132
(9
)%
—
%
(9
)%
Gross Margin
82.7
%
84.0
%
Operating Expenses
414
423
(2
)%
—
%
(2
)%
Other (income)/deductions-net
—
—
*
*
*
U.S. Earnings
$
1,534
$
1,709
(10
)%
—
%
(10
)%
International:
Revenue
$
2,322
$
2,070
12
%
5
%
7
%
Cost of Sales
674
616
9
%
6
%
3
%
Gross Profit
1,648
1,454
13
%
4
%
9
%
Gross Margin
71.0
%
70.2
%
Operating Expenses
347
334
4
%
5
%
(1
)%
Other (income)/deductions-net
1
1
*
*
*
International Earnings
$
1,300
$
1,119
16
%
5
%
11
%
Total Reportable Segments
$
2,834
$
2,828
—
%
2
%
(2
)%
Other business activities(c)
(276
)
(262
)
5
%
Reconciling Items:
Corporate(d)
(630
)
(602
)
5
%
Purchase accounting adjustments(e)
(58
)
(65
)
(11
)%
Acquisition and divestiture-related costs(f)
(4
)
(1
)
*
Certain significant items(g)
(108
)
(54
)
*
Other unallocated(h)
(134
)
(159
)
(16
)%
Total Earnings(i)
$
1,624
$
1,685
(4
)%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.
(c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.
(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.
(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.
(f) Acquisition and divestiture-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as costs associated with divesting and disintegrating a portion of our business.
(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition, costs related to our business process transformation program, as well as the impact of divestiture gains and losses.
(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.
(i) Defined as income before provision for taxes on income.
Animal health company Zoetis cut its annual forecasts on Thursday after missing Wall Street estimates for second-quarter revenue, as softer demand for pet healthcare products and increased competition weighed.
The upcoming report from Zoetis (ZTS - Free Report) is expected to reveal quarterly earnings of $1.84 per share, indicating an increase of 4.6% compared to the year-ago period. Analysts forecast revenues of $2.49 billion, representing an increase of 1.3% year over year.
The current level reflects a downward revision of 0.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Zoetis metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Revenues- Livestock' will reach $678.90 million. The estimate points to a change of +6.4% from the year-ago quarter.
The consensus estimate for 'Revenues- Contract Manufacturing & Human Health' stands at $35.13 million. The estimate suggests a change of +3.3% year over year.
Based on the collective assessment of analysts, 'Revenues- Companion Animal' should arrive at $1.77 billion. The estimate suggests a change of -0.9% year over year.
The average prediction of analysts places 'Geographic Revenues- U.S.' at $1.33 billion. The estimate indicates a change of -2.2% from the prior-year quarter.
Analysts forecast 'Geographic Revenues- U.S.- Livestock' to reach $191.10 million. The estimate suggests a change of +6.2% year over year.
The combined assessment of analysts suggests that 'Geographic Revenues- International- Companion Animal' will likely reach $651.08 million. The estimate indicates a change of +6.4% from the prior-year quarter.
Analysts' assessment points toward 'Geographic Revenues- International Revenue' reaching $1.14 billion. The estimate indicates a change of +6.8% from the prior-year quarter.
According to the collective judgment of analysts, 'Geographic Revenues- International- Livestock' should come in at $491.12 million. The estimate indicates a change of +7.2% from the prior-year quarter.
The consensus among analysts is that 'Geographic Revenues- U.S.- Companion Animal' will reach $1.14 billion. The estimate indicates a change of -3.5% from the prior-year quarter.
View all Key Company Metrics for Zoetis here>>>
Shares of Zoetis have demonstrated returns of +2.2% over the past month compared to the Zacks S&P 500 composite's +1.7% change. With a Zacks Rank #4 (Sell), ZTS is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Key Takeaways Zoetis is expected to report Q2 revenues of $2.49B and earnings of $1.84 per share on Aug. 6, 2026. ZTS may see weaker U.S. sales amid competition and Librela pressure, offset by international growth.Zoetis could benefit from demand for Apoquel, Cytopoint, Simparica Trio and livestock products. Zoetis, Inc. (ZTS - Free Report) is slated to report second-quarter results on Aug. 6, 2026, before the opening bell.
The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $2.49 billion. The consensus mark for earnings is pinned at $1.84 per share.
Let's see how things might have shaped up for Zoetis in the soon-to-be-reported quarter.
Factors to Consider Regarding ZTS’ Q2 EarningsZoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments — the United States and International.
First-quarter revenues in the U.S. segment are likely to have decreased from the year-ago quarter, primarily due to lower sales of Zoetis’ companion animal products and an increasingly competitive landscape. The Zacks Consensus Estimate for revenues generated from this segment is pegged at $1.33 billion.
Revenues from the International segment are expected to have increased in the to-be-reported quarter due to higher sales of companion animal and livestock products. The Zacks Consensus Estimate for revenues generated from this segment is pegged at $1.14 billion.
Year to date, Zoetis shares have plunged 38.6% compared with the industry’s 4.5% decline.
Image Source: Zacks Investment Research
Companion animal products sales, particularly ZTS’ parasiticides portfolio, including Simparica and ProHeart franchises, and its key dermatology products, including Apoquel and Cytopoint, are expected to have driven revenues in both the U.S. and International segments in the to-be-reported quarter.
However, Zoetis’ monoclonal antibody products for osteoarthritis pain, Librela for dogs and Solensia for cats, are expected to have posted a decline in sales in the U.S. segment due to fears of side effects in some dogs.
Apoquel is also approved as the first and only chewable treatment in the United States for controlling pruritus related to allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. The drug’s expanded label is likely to have boosted sales in the first quarter.
In 2025, the FDA approved a new indication for Zoetis’ Simparica Trio to prevent flea tapeworm infections by targeting and killing vector fleas in treated dogs. With this approval, the triple combo drug is now the only canine combination parasiticide indicated to prevent flea tapeworm infections at the source by eliminating carrier fleas before they can transmit the parasite. The label expansion is expected to have driven sales in the to-be-reported quarter.
Zoetis' livestock product sales are expected to have increased in the second quarter, supported by continued broad-based strength across its core species portfolio. In the United States, growth is likely to have been driven by cattle, poultry and swine products, while the International segment is expected to have benefited from broad-based demand across cattle, swine, poultry and fish.
ZTS Earnings Surprise HistoryZoetis has a mixed earnings surprise history so far. The bottom line surpassed estimates in three of the trailing four quarters and missed on the remaining occasion, delivering an average surprise of 3.58%. In the last reported quarter, the company delivered a negative surprise of 4.97%.
Earnings Whispers for ZTSOur proven model does not predict an earnings beat for Zoetis this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: ZTS has an Earnings ESP of -0.75%.
Zacks Rank: Zoetis currently carries a Zacks Rank #4 (Sell).
Stocks to ConsiderHere are some stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Harmony Biosciences (HRMY - Free Report) has an Earnings ESP of +14.14% and sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of HRMY have lost 5.9% year to date. The company’s earnings missed estimates in each of the trailing four quarters, delivering an average negative surprise of 25.16%. Harmony is scheduled to report second-quarter results on Aug. 4, before the opening bell.
ACADIA Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +25.00% and a Zacks Rank #2 at present.
Shares of ACAD have lost 3.1% year to date. The company’s earnings beat estimates in three of the trailing four quarters and missed on the remaining occasion, delivering an average surprise of 20.83%. Acadia is scheduled to report second-quarter results on Aug. 4.
CRISPR Therapeutics (CRSP - Free Report) has an Earnings ESP of +1.94% and a Zacks Rank #3 at present.
Shares of CRSP have lost 8.4% year to date. CRISPR’s earnings beat estimates in two of the trailing four quarters and missed on the remaining two occasions, delivering an average negative surprise of 1.95%.
Zoetis (ZTS - Free Report) closed at $76.92 in the latest trading session, marking a +2.08% move from the prior day. This move outpaced the S&P 500's daily gain of 0.02%. On the other hand, the Dow registered a gain of 0.51%, and the technology-centric Nasdaq decreased by 0.18%.
The stock of animal health company has fallen by 0.97% in the past month, lagging the Medical sector's gain of 3.09% and the S&P 500's gain of 0.77%.
Investors will be eagerly watching for the performance of Zoetis in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 6, 2026. The company's earnings per share (EPS) are projected to be $1.84, reflecting a 4.55% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $2.49 billion, reflecting a 1.29% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $6.89 per share and a revenue of $9.72 billion, signifying shifts of +7.49% and +2.66%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Zoetis. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.13% fall in the Zacks Consensus EPS estimate. Right now, Zoetis possesses a Zacks Rank of #4 (Sell).
From a valuation perspective, Zoetis is currently exchanging hands at a Forward P/E ratio of 10.94. This expresses a discount compared to the average Forward P/E of 17.14 of its industry.
It's also important to note that ZTS currently trades at a PEG ratio of 1.17. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical - Drugs industry held an average PEG ratio of 1.72.
The Medical - Drugs industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 94, finds itself in the top 39% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
New York, New York--(Newsfile Corp. - July 27, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/ZTS.
Zoetis Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements concerning the growth, competitive positioning, market share, and veterinarian adoption of key products within the Companion Animal segment while failing to disclose that:
veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; Zoetis' Simparica Trio was losing significant market share to a lower-priced competing canine parasiticide with broader indicated use in a slowing overall market; and Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.What's Next for Zoetis Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/ZTS, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Zoetis you have until July 27, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Zoetis Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Zoetis Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299407
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - July 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and touted growing market share, strong veterinarian adoption, and accelerating sales growth across Zoetis' flagship Companion Animal products and/or failed to disclose that: (1) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306670
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/ZTS.
Zoetis Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements concerning the growth, competitive positioning, market share, and veterinarian adoption of key products within the Companion Animal segment while failing to disclose that:
(1) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs;
(2) Zoetis’ Simparica Trio was losing significant market share to a lower-priced competing canine parasiticide with broader indicated use in a slowing overall market; and
(3) Zoetis’ dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.
What's Next for Zoetis Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/ZTS. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Zoetis you have until July 27, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Zoetis Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Zoetis Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Melissa Fortunato Encourage Investors Who Suffered Losses In Zoetis (ZTS) To Contact Them Directly To Discuss Their Options
, /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS).
IF YOU SUFFERED A LOSS ON YOUR ZOETIS INVESTMENTS, CLICK HERE BEFORE JULY 27, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT
What Is The Lawsuit About?
The complaint filed alleges that, between January 14, 2025 and May 6, 2026, Defendants failed to disclose to investors that: (1) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zoetis Inc. (NYSE: ZTS).
Shareholders who purchased shares of ZTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (ii) Zoetis’ Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (iii) Zoetis’ dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.
DEADLINE: July 27, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/zoetis-inc-loss-submission-form-2/?id=195836&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ZTS during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 27, 2026. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903
SummaryZoetis Inc. trades at a 45% discount to fair value despite resilient fundamentals and long-term growth prospects.ZTS's Q1 2026 saw 2.9% revenue growth and 8.5% adjusted EPS growth, with livestock offsetting domestic pet care weakness.Forward P/E of 10.5 is well below its 10-year average; a fair value multiple of 19 is justified given a 7.5% EPS growth consensus.A dividend yield of 2.8% and a low payout ratio support continued high single-digit dividend growth, despite U.S. softness and competitive risks.Looking for more investing ideas like this one? Get them exclusively at The Dividend Kings. Learn More » EMS-FORSTER-PRODUCTIONS/DigitalVision via Getty Images
Co-authored by Kody's Dividends
How does one shift market sentiment?
That's a question management teams ask themselves regularly. If you could unlock the formula to control market sentiment, you could make a killing in quick trades. Market sentiment
4.98K Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of ACN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Kody's Dividends, Justin Law, and Rachel Kaufman are part of the Dividend Kings team
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
New York, New York--(Newsfile Corp. - July 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and touted growing market share, strong veterinarian adoption, and accelerating sales growth across Zoetis' flagship Companion Animal products and/or failed to disclose that: (1) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306332
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - July 23, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/ZTS.
Zoetis Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements concerning the growth, competitive positioning, market share, and veterinarian adoption of key products within the Companion Animal segment while failing to disclose that:
veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; Zoetis' Simparica Trio was losing significant market share to a lower-priced competing canine parasiticide with broader indicated use in a slowing overall market; and Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.What's Next for Zoetis Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/ZTS, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Zoetis you have until July 27, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Zoetis Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Zoetis Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299406
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Zoetis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until July 27, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Zoetis securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On May 7, 2026, Zoetis reported financial results for the first quarter of 2026. Among other items, Zoetis reported net income of $601 million, flat year over year, and cut its full year 2026 profit guidance to between $6.85 and $7 a share, down from prior guidance of $7.00 to $7.10 a share. In the earnings release, CEO Kristin Peck said that "the first quarter unfolded in a more challenging operating environment than we anticipated. Pet owners demonstrated increased price sensitivity, resulting in a decline in veterinary visits and softer demand[.]"
On this news, Zoetis's stock price fell $23.91 per share, or 21.5%, to close at $87.31 per share on May 7, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/ZTS.
Zoetis Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements concerning the growth, competitive positioning, market share, and veterinarian adoption of key products within the Companion Animal segment while failing to disclose that:
(1) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs;
(2) Zoetis’ Simparica Trio was losing significant market share to a lower-priced competing canine parasiticide with broader indicated use in a slowing overall market; and
(3) Zoetis’ dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.
What's Next for Zoetis Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/ZTS. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Zoetis you have until July 27, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Zoetis Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Zoetis Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive.
Should You Join The Zoetis Class Action Lawsuit:
Do you, or did you, own shares of Zoetis Inc. (NYSE: ZTS)?
Did you purchase your shares between January 14, 2025 and May 6, 2026, inclusive?
Did you lose money in your investment in Zoetis Inc.?
What To Do Next:
Investors are encouraged to act promptly and submit a form at Zoetis Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].
If you wish to serve as lead plaintiff for the Class, you must file papers by July 27, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About The Lawsuit:
The lawsuit alleges that defendants made materially false and misleading statements and omissions regarding the Company’s business operations, growth prospects, and financial stability. As a result of these alleged misrepresentations, Zoetis securities traded at artificially inflated prices during the Class Period. When the truth was disclosed, investors allegedly suffered significant losses.
About Bernstein Liebhard:
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”), of the important July 27, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and touted growing market share, strong veterinarian adoption, and accelerating sales growth across Zoetis’ flagship Companion Animal products and/or failed to disclose that: (1) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis’ Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis’ dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
New York, New York--(Newsfile Corp. - July 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and touted growing market share, strong veterinarian adoption, and accelerating sales growth across Zoetis' flagship Companion Animal products and/or failed to disclose that: (1) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306210
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming July 27, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) securities between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”).
IF YOU ARE AN INVESTOR WHO LOST MONEY ON ZOETIS INC. (ZTS), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT.
What Happened?
On August 5, 2025, Zoetis released its second quarter 2025 financial results, reporting weakened demand trends within its Companion Animal portfolio.
On this news, Zoetis’ stock price fell $5.69, or 3.8%, to close at $146.12 per share on August 5, 2025, thereby injuring investors.
Then, on November 4, 2025, Zoetis released its third quarter 2025 financial results, revealing slowed growth across its key Companion Animal franchises and disclosing continued weakness in sales of its canine pain treatment, Librela, and increased competitive pressure in dermatology and parasiticides. The Company also lowered its full year sales outlook.
On this news, Zoetis’ stock price fell $19.89, or 13.8%, to close at $124.46 per share on November 4, 2025.
Then, on May 7, 2026, Zoetis released its first quarter 2026 financial results, reporting slowing overall revenue growth, declining Companion Animal sales performance, and worsening results across its key dermatology and parasiticides franchises, stating that “competition intensified across key pet care categories, including dermatology and parasiticides,” that “pet owners demonstrated increased price sensitivity,” and that “these new entrants have not yet translated into overall market expansion.”
The Company also explained that “price has played a larger role in the decision process,” that “[s]hare loss is being amplified by a derm market with declining patient volume in the clinic,” and that contraction in the parasiticides market was negatively impacting prescription volumes and compliance. In addition, the Company admitted that it was operating in “a more price sensitive and competitive environment” and further reduced its 2026 growth outlook based on continuing competitive and operating pressures.
On this news, Zoetis’ stock price fell $23.91, or 21.5%, to close at $87.31 per share on May 7, 2026, thereby injuring investors further.
What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis’ Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis’ dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
If you purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, the deadline to seek appointment as the lead plaintiff in the securities fraud class action is July 27, 2026.
Contact Us To Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact us:
Frank R. Cruz
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Email us at: [email protected]
Call us at: 310-914-5007
Visit our website at www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW
If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
[url="]The Law Offices of Frank R. Cruz[/url] reminds investors of the upcoming July 27, 2026 deadline to participate as a lead plaintiff in the securities fra
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union (EU) member states. Portela is the first long-acting anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy for cats, designed to alleviate pain associated with osteoarthritis (OA) for up to three months with a single subcutaneous injection. Backed by nearly a decade of science and research, Portela demonstrated effectiveness in al.
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) investors of the July 27, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Zoetis Class Action Lawsuit : Do you, or did you, own shares of Zoetis Inc. (NYSE: ZTS)?
LOS ANGELES, July 20, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Zoetis Inc. (“Zoetis” or “the Company”) (NYSE: ZTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s securities between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before July 27, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Zoetis suffered from weakening veterinarian prescription growth for its Librela medication after the FDA issued safety warnings about neurological complications in dogs. The Company’s Trio product lost market share to competitors. The Company’s Apoquel and Cytopoint dermatology products lost market share to newly launched competing treatments for dogs. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Zoetis, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335 [email protected]
In the latest close session, Zoetis (ZTS - Free Report) was down 1.12% at $75.35. The stock's change was less than the S&P 500's daily gain of 0.89%. Elsewhere, the Dow gained 0.74%, while the tech-heavy Nasdaq added 1.29%.
Shares of the animal health company witnessed a gain of 0.41% over the previous month, trailing the performance of the Medical sector with its gain of 4.77%, and outperforming the S&P 500's loss of 0.63%.
The upcoming earnings release of Zoetis will be of great interest to investors. The company's earnings report is expected on August 6, 2026. The company is expected to report EPS of $1.85, up 5.11% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $2.49 billion, up 1.42% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $6.89 per share and a revenue of $9.72 billion, indicating changes of +7.49% and +2.69%, respectively, from the former year.
Any recent changes to analyst estimates for Zoetis should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.09% lower within the past month. Zoetis presently features a Zacks Rank of #4 (Sell).
Looking at valuation, Zoetis is presently trading at a Forward P/E ratio of 11.06. This valuation marks a discount compared to its industry average Forward P/E of 17.11.
Also, we should mention that ZTS has a PEG ratio of 1.19. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ZTS's industry had an average PEG ratio of 1.73 as of yesterday's close.
The Medical - Drugs industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 100, positioning it in the top 41% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
New York, New York--(Newsfile Corp. - July 21, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/ZTS.
Zoetis Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements concerning the growth, competitive positioning, market share, and veterinarian adoption of key products within the Companion Animal segment while failing to disclose that:
veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; Zoetis' Simparica Trio was losing significant market share to a lower-priced competing canine parasiticide with broader indicated use in a slowing overall market; and Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.What's Next for Zoetis Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/ZTS, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Zoetis you have until July 27, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Zoetis Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Zoetis Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299405
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Zoetis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until July 27, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Zoetis securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On May 7, 2026, Zoetis reported financial results for the first quarter of 2026. Among other items, Zoetis reported net income of $601 million, flat year over year, and cut its full year 2026 profit guidance to between $6.85 and $7 a share, down from prior guidance of $7.00 to $7.10 a share. In the earnings release, CEO Kristin Peck said that “the first quarter unfolded in a more challenging operating environment than we anticipated. Pet owners demonstrated increased price sensitivity, resulting in a decline in veterinary visits and softer demand[.]”
On this news, Zoetis’s stock price fell $23.91 per share, or 21.5%, to close at $87.31 per share on May 7, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
